Positive Patient Stories™

Paratek Pharmaceuticals News

Webcast ImageWebcast
Paratek Pharmaceuticals Inc Q1 2019 Earnings Conference Call (Replay)
05/08/19 at 4:30 p.m. ET
Paratek Pharmaceuticals Inc Q1 2019 Earnings Conference Call
Wednesday, May 8, 2019 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle  
05/08/19Paratek’s NUZYRA™ (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market 
04/30/19Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019 
04/15/19Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations 
04/04/19Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019 
04/01/19Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award 
03/28/19Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference 
03/18/19Paratek Pharmaceuticals Announces Management Change 
03/01/19Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
03/01/19Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference 
02/27/19Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results 
02/14/19Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference 
02/13/19Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019 
02/06/19New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections 
02/05/19Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States 
02/01/19Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
01/02/19Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.